Imunon Inc
IMNN1.140USD
+0.724+174.37%
Handelsschluss 05/23, 16:00（ET）Kurse um 15 Minuten verzögert
16.67MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Imunon Inc Unternehmen
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
Unternehmensinformationen
Unternehmens-codeIMNN
Name des UnternehmensImunon Inc
IPO-datumOct 27, 1993
Gegründet am2000
CEODr. Stacy R. Lindborg, Ph.D.
Anzahl der mitarbeiter25
WertpapierartOrdinary Share
GeschäftsjahresendeOct 27
Addresse997 Lenox Dr Ste 100
StadtLAWRENCEVILLE
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl08648
Telefon16098969100
Websitehttps://imunon.com/
Unternehmens-codeIMNN
IPO-datumOct 27, 1993
Gegründet am2000
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Michael H. Tardugno
Mr. Michael H. Tardugno
Executive Chairman of the Board
Executive Chairman of the Board
69.14K
+66.55%
Dr. Donald P. Braun, Ph.D.
Dr. Donald P. Braun, Ph.D.
Independent Director
Independent Director
25.60K
--
Dr. Sebastien Hazard
Dr. Sebastien Hazard
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
20.00K
--
Dr. Khursheed Anwer, Ph.D.
Dr. Khursheed Anwer, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
12.86K
+350.26%
Mr. Frederick J. (Fred) Fritz
Mr. Frederick J. (Fred) Fritz
Independent Director
Independent Director
11.77K
--
Ms. Susan Eylward
Ms. Susan Eylward
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
--
--
Dr. Stacy R. Lindborg, Ph.D.
Dr. Stacy R. Lindborg, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. David (Dave) Gaiero, CPA
Mr. David (Dave) Gaiero, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Douglas Vincent Faller, M.D., Ph.D.
Dr. Douglas Vincent Faller, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Christine A. Pellizzari, J.D.
Ms. Christine A. Pellizzari, J.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Michael H. Tardugno
Mr. Michael H. Tardugno
Executive Chairman of the Board
Executive Chairman of the Board
69.14K
+66.55%
Dr. Donald P. Braun, Ph.D.
Dr. Donald P. Braun, Ph.D.
Independent Director
Independent Director
25.60K
--
Dr. Sebastien Hazard
Dr. Sebastien Hazard
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
20.00K
--
Dr. Khursheed Anwer, Ph.D.
Dr. Khursheed Anwer, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
12.86K
+350.26%
Mr. Frederick J. (Fred) Fritz
Mr. Frederick J. (Fred) Fritz
Independent Director
Independent Director
11.77K
--
Ms. Susan Eylward
Ms. Susan Eylward
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionäre
Update-Zeit: Fri, May 16
Update-Zeit: Fri, May 16
Aktionärsstatistik
Art
Aktionärsstatistik
Aktionäre
Anteil
Geode Capital Management, L.L.C.
0.98%
Tardugno (Michael H)
0.47%
BlackRock Institutional Trust Company, N.A.
0.40%
Le (Goff Corinne)
0.36%
The Vanguard Group, Inc.
0.33%
Other
97.45%
Aktionärsstatistik
Aktionäre
Anteil
Geode Capital Management, L.L.C.
0.98%
Tardugno (Michael H)
0.47%
BlackRock Institutional Trust Company, N.A.
0.40%
Le (Goff Corinne)
0.36%
The Vanguard Group, Inc.
0.33%
Other
97.45%
Art
Aktionäre
Anteil
Investment Advisor/Hedge Fund
1.68%
Individual Investor
1.52%
Investment Advisor
0.41%
Venture Capital
0.15%
Hedge Fund
0.10%
Other
96.14%
Institutionelle Beteiligung
Update-Zeit: Mon, Mar 3
Update-Zeit: Mon, Mar 3
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q1
49
648.18K
4.43%
-1.83M
2024Q4
52
608.75K
4.16%
-1.78M
2024Q3
50
1.20M
8.34%
-536.74K
2024Q2
48
484.50K
4.81%
-359.07K
2024Q1
49
447.12K
4.68%
-585.60K
2023Q4
59
755.78K
7.96%
-79.04K
2023Q3
65
452.55K
4.85%
-471.22K
2023Q2
68
440.18K
4.85%
-489.81K
2023Q1
80
515.97K
6.03%
-572.90K
2022Q4
81
529.26K
7.22%
-671.21K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Geode Capital Management, L.L.C.
139.50K
0.95%
+13.57K
+10.78%
Dec 31, 2024
Tardugno (Michael H)
69.14K
0.47%
+27.63K
+66.55%
Feb 21, 2025
BlackRock Institutional Trust Company, N.A.
58.22K
0.4%
--
--
Dec 31, 2024
Le (Goff Corinne)
53.00K
0.36%
--
--
Feb 21, 2025
The Vanguard Group, Inc.
48.81K
0.33%
--
--
Dec 31, 2024
Lindborg (Stacy R. Ph.D.)
28.06K
0.19%
+3.06K
+12.22%
Feb 21, 2025
Braun (Donald P)
25.60K
0.18%
--
--
Feb 21, 2025
XTX Markets LLC
21.41K
0.15%
+21.41K
--
Dec 31, 2024
Northern Trust Investments, Inc.
21.64K
0.15%
+18.40K
+567.70%
Dec 31, 2024
State Street Global Advisors (US)
21.30K
0.15%
--
--
Dec 31, 2024
Mehr Anzeigen
Verbundene ETFs
Update-Zeit: Tue, May 6
Update-Zeit: Tue, May 6
Name
Anteil
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Feb 28, 2022
Merger
15<1
Feb 28, 2022
Merger
15<1
Feb 28, 2022
Merger
15<1
Feb 28, 2022
Merger
15<1
Datum
Art
Verhältnis
Feb 28, 2022
Merger
15<1
Feb 28, 2022
Merger
15<1
Feb 28, 2022
Merger
15<1
Feb 28, 2022
Merger
15<1
